AbbVie (ABBV) and partner, Genmab (GMAB) , announced that the European Commission has granted conditional marketing authorization for the expanded use of Tepkinly (epcoritamab) to treat relapsed or refractory follicular lymphoma (FL) after two or more therapies. R/R FL is a particularly difficult-to-treat form of cancer, especially in later lines of therapy, for which there is currently no standard of care treatment.The encouraging regulatory update follows the positive opinion that was adopted by the advis ...

TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyFL is an incurable form of non-Hodgkin's lymphoma (NHL), with about 13,000 estimated cases in Western Europe alone each year1NORTH CHICAGO, Ill., Aug. 19, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that ...

These stocks dividends continue to flow and grow.What do income investors like better than a stock that pays a juicy dividend yield? The answer is easy: A stock with a juicy dividend yield that's likely to grow its dividend payout over time.Such stocks aren't as hard to find as some might think. Here are three high-yield dividend stocks to buy now that have increased their dividends for 25 years or more.1. AbbVieAbbVie's (ABBV 0.26%) forward dividend yield of over 3.2% isn't as high as it was earlier this y ...

This list of top-selling drugs could look drastically different in a few years.You might think that if a drugmaker has a top-selling drug, it would be a lock to be a top-performing stock and a no-brainer buy. That may be true in some cases. In others, it can be a source of risk as investors grow concerned about what a company's growth opportunities will look like after the relevant patent expires, especially when the drug accounts for a significant chunk of the company's sales.The three top-selling drugs in ...

文章核心观点 - 文章介绍了3家具有高股息和持续增长股息的公司,包括制药公司AbbVie、电信公司Verizon和房地产投资信托公司Prologis [1][2][3] - 这些公司都具有良好的财务状况,能够为投资者提供稳定的股息收益,是退休投资者的理想选择 [2] AbbVie - AbbVie是一家制药公司,目前股息收益率为3.3%,高于标准普尔500指数的1.4% [4] - 公司在过去5年内将股息增加了45%,年复合增长率达7.7% [4] - 公司除了提供高股息,还有良好的增长前景,通过并购等方式来拓展业务 [5] - 公司面临专利到期的挑战,但预计明年将恢复强劲增长,长期目标为高单位数的复合增长率 [6] - 公司盈利稳定,股价估值合理,是一个全面的投资标的 [7] Verizon - Verizon是一家电信巨头,目前股息收益率高达6.5% [8] - 公司虽然不是高增长型,但能为投资者提供稳定的股息收益 [9] - 过去5年内,公司股息增长10%,年复合增长率约2% [10] - 即使未来增长缓慢,但凭借高股息收益,仍能为退休投资者带来可观的收益 [10] Prologis - Prologis是一家房地产投资信托公司,主要投资于仓储物流设施 [11] - 公司股息收益率为3.2%,高于平均水平 [12] - 过去5年内,公司股息增长81%,年复合增长率达12.6% [13] - 公司的核心经营指标远高于股息支付,未来有望继续大幅增加股息 [12][13]

Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future. Many of these stocks have fallen out of fashion in the tech-fueled AI revolution. But in the last month, many of these stocks are increasing as investors feel more bullish about the economy.  Investors who reinvest those dividends have the opportunity to increase their total return on th ...

All of these stocks can provide steady income to retired investors.Many retirees are investors for a good reason: They can't rely entirely on Social Security to fund their retirement. Investing wisely provides a means to retire comfortably.Three Motley Fool contributors think they have found stocks to buy that retirees should absolutely love. All three offer juicy dividend yields. Here are their cases for AbbVie (ABBV -0.25%), Bristol Myers Squibb (BMY -0.28%), and Gilead Sciences (GILD -2.55%). Everything ...

Eric Francis Only when the tide goes out do you discover who's been swimming naked. - Warren Buffett Written by Sam Kovacs Introduction Every day, 10,000 Baby Boomers reach retirement age. This means that in July, as many as 300,000 Americans could have retired. Many of those have had a timing issue with retiring, depending on how they invested their savings, and I'm going to demonstrate this in this article. I'll also show you how all of this trouble could have been avoided by building what we like to ...

财务概况 - 公司2024年上半年全球净收入为268亿美元，同比增长3%（实际汇率）和4%（固定汇率）[184] - 公司2024年上半年稀释每股收益为1.53美元，包含无形资产摊销、或有对价公允价值变动等成本[185] - 公司2024年上半年美国市场净收入为201.47亿美元，增长1.1%（实际和固定汇率）[209] - 公司2024年上半年国际市场净收入为66.25亿美元，增长7.4%（实际汇率）和12.1%（固定汇率）[209] - 公司总净收入为144.62亿美元，同比增长4.3%[211] - 国际市场其他神经科学产品收入增长超过100%[211] - Skyrizi产品净收入增长46%[214] - Rinvoq产品净收入增长59%[215] - Imbruvica产品全球收入下降8%[216] - Venclexta产品收入增长16%[217] - Elahere产品收入为1.28亿美元[218] - Botox Cosmetic产品收入增长9%[219] - Juvederm Collection产品收入下降3%[220] - Botox Therapeutic产品收入增长10%[221] - 公司在前六个月结束于2024年6月30日的研发里程碑费用为95百万美元，而2023年同期为78百万美元[231] - 公司在前六个月结束于2024年6月30日的净利息费用为959百万美元，相比2023年同期的908百万美元有所增加[233] - 公司在前六个月结束于2024年6月30日的其他费用净额为1,931百万美元，而2023年同期为3,216百万美元[234] - 公司在前六个月结束于2024年6月30日的有效税率从2023年同期的26%增加到30%[238] - 公司在前六个月结束于2024年6月30日的经营活动现金流为6,311百万美元，相比2023年同期的10,512百万美元有所减少[239] - 公司在前六个月结束于2024年6月30日的投资活动现金流为-10,690百万美元，其中包括用于收购ImmunoGen的98亿美元现金[241] - 公司在前六个月结束于2024年6月30日的融资活动现金流为4,722百万美元，其中包括发行无担保高级票据总计150亿美元用于资助ImmunoGen和Cerevel Therapeutics的收购[242] - 公司在前六个月结束于2024年6月30日的现金股息支付为55亿美元，相比2023年同期的53亿美元有所增加[243] - 公司宣布在2024年6月21日，董事会宣布每季度现金股息为1.55美元每股，将于2024年8月15日支付[244] - 公司在2024年2月16日，董事会授权增加50亿美元的股票回购授权，前六个月结束于2024年6月30日，公司回购了5百万股，总计959百万美元[245] 产品线扩展与收购 - 公司完成对ImmunoGen的收购，进一步强化肿瘤治疗产品线，特别是抗体药物偶联物（ADC）疗法[181] - 公司宣布Rinvoq在多项临床试验中取得积极结果，包括治疗非节段性白癜风、巨细胞动脉炎等[190][191][192][193] - 公司宣布Skyrizi获得FDA批准用于治疗中度至重度溃疡性结肠炎，并在欧洲获得批准用于类似适应症[194][195] - 公司宣布Elahere获得FDA全面批准用于治疗叶酸受体α阳性、铂类耐药的卵巢癌[200] - 公司宣布Epkinly获得FDA加速批准用于治疗复发或难治性滤泡性淋巴瘤，并在欧洲获得积极推荐[199] - 公司宣布Juvederm Voluma XC获得FDA批准用于治疗成人中度至重度颞部凹陷[204] 产品收入变化 - 公司免疫学产品Humira在美国市场的收入从2023年的34.52亿美元下降至2024年的23.6亿美元，下降幅度为31.6%[210] - 公司免疫学产品Skyrizi在美国市场的收入从2023年的16.34亿美元增长至2024年的23.4亿美元，增长幅度为43.2%[210] - 公司免疫学产品Rinvoq在美国市场的收入从2023年的6.45亿美元增长至2024年的10.17亿美元，增长幅度为57.9%[210] - 公司肿瘤学产品Imbruvica在美国市场的收入从2023年的6.66亿美元下降至2024年的5.95亿美元，下降幅度为10.6%[210] - 公司肿瘤学产品Venclexta在美国市场的收入从2023年的2.65亿美元增长至2024年的3亿美元，增长幅度为12.8%[210] - 公司美学产品Botox Cosmetic在美国市场的收入从2023年的4.2亿美元增长至2024年的4.5亿美元，增长幅度为7.1%[210] - 公司神经科学产品Botox Therapeutic在美国市场的收入从2023年的6.14亿美元增长至2024年的6.69亿美元，增长幅度为8.9%[210] - 公司神经科学产品Vraylar在美国市场的收入从2023年的6.57亿美元增长至2024年的7.73亿美元，增长幅度为17.5%[210] - 公司神经科学产品Ubrelvy在美国市场的收入从2023年的1.94亿美元增长至2024年的2.27亿美元，增长幅度为16.6%[210] - 公司神经科学产品Qulipta在美国市场的收入从2023年的0.95亿美元增长至2024年的1.46亿美元，增长幅度为52.8%[210]

GeorgePeters Introduction Things aren't going so well anymore. The AI-fueled tech rally has stalled, and all eyes are now on the "real" economy, which is showing some serious cracks. The just-released unemployment numbers, for example, came in much lower than expected, with nonfarm payrolls indicating just 114 thousand new jobs in July. The prior month's gain was revised from 206 thousand to 179 thousand. The unemployment rate rose to 4.3%, 20 basis points higher than expected. Bloomberg These numbers c ...